Aβ Peptide Fragment Segmentation for Angiogenesis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and related vascular abnormalities fail to effectively address the role of pathological angiogenesis, with Aβ peptides exhibiting both anti-angiogenic and pro-angiogenic properties depending on their dosage and conformation, leading to inconsistent therapeutic outcomes.
Innovation Solution
Biologically active fragments of Aβ peptides, specifically those 8 to 39 amino acids in length, such as Aβ1-28, Aβ10-35, and Aβ12-28, are used as anti-angiogenic agents to treat conditions mediated by undesired angiogenesis, administered alone or in combination with other therapeutic agents, and their diagnostic methods and kits are developed for detection and measurement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full length Aβ peptides are used as therapeutic agents, then anti-angiogenic activity is achieved, but pro-angiogenic effects occur at high doses and inconsistent therapeutic outcomes result
Solution Approach 1:
The patent divides the full-length Aβ peptide (42-43 amino acids) into smaller functional fragments (8-39 amino acids), isolating the anti-angiogenic active site while eliminating the pro-angiogenic effects associated with full-length peptides at high doses. This segmentation allows the therapeutic fragment to maintain anti-angiogenic activity without the harmful pro-angiogenic properties.
Solution Approach 2:
The patent extracts and isolates the specific anti-angiogenic functional domain from the full-length Aβ peptide sequence. By taking out only the necessary anti-angiogenic activity and removing the rest of the peptide structure, the invention creates a purified therapeutic fragment that eliminates the pro-angiogenic effects present in the complete peptide.
2Object-affected harmful factors
If Aβ peptides are administered to treat Alzheimer's disease, then vascular abnormalities are addressed, but angiogenesis remains impaired and blood flow reduction persists
Solution Approach 1:
The patent modifies the molecular parameters of the Aβ peptide by changing its length from full-length (42-43 amino acids) to fragmented forms (8-39 amino acids). This parameter change alters the biological activity profile, enabling the fragment to inhibit pathological angiogenesis while preserving normal vascular function and blood flow.
3Measurement precision
If diagnostic methods are developed to detect Aβ peptide fragments, then therapeutic monitoring is enabled, but measurement complexity increases
Solution Approach 1:
The patent creates diagnostic tools that use molecular copies or analogs of the Aβ peptide fragments as detection targets. By using simplified molecular probes that mimic the fragment structure, the invention enables accurate detection without requiring complex instrumentation, maintaining high measurement precision while minimizing device complexity.
Data Source
AI summary
Provided are Aβ peptide fragments that are useful in inhibiting angiogenesis. Also provided are methods for the treatment of pathological or unwanted angiogenesis and conditions and diseases associated therewith by administering an effective amount of an Aβ fragment. In a particular embodiment, the peptide fragment includes the sequence HHQKLVFF.